Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | Managing patients with transplant-ineligible BDPCN with tagraxofusp

Marco Herling • 25 Apr 2023
EBMT 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

Marco Herling, MD, University of Leipzig, Leipzig, Germany, comments on the management of transplant-ineligible patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), explaining that patients should be treated with tagraxofusp due to its tolerable toxicity profile. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marco Herling

1:00
Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
Marco Herling • 25 Apr 2023
1:41
Improvements in the awareness and diagnosis of BPDCN
Marco Herling • 25 Apr 2023
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023
3:07
Frontline treatment in BPDCN & the best route to allogeneic transplantation
Marco Herling • 25 Apr 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals